Clinical Trials /

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

NCT03395080

Description:

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

Related Conditions:
  • Endometrial Carcinoma
  • Fallopian Tube Carcinoma
  • Malignant Peritoneal Neoplasm
  • Ovarian Carcinoma
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer (P204)
  • Official Title: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer

Clinical Trial IDs

  • ORG STUDY ID: DEK-DKK1-P204
  • NCT ID: NCT03395080

Conditions

  • Endometrial Cancer
  • Uterine Cancer
  • Ovarian Cancer

Interventions

DrugSynonymsArms
PaclitaxelTaxolGroup 2
DKN-01Group 1

Purpose

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer

Detailed Description

      This study employs a "basket" design to concurrently investigate DKN-01 as monotherapy and in
      combination with paclitaxel in patients with recurrent epithelial endometrial cancer (EEC) or
      recurrent epithelial ovarian cancer (EOC) (see Study Design for details). Thus, 4 distinct
      patient groups are being independently investigated:

        1. DKN-01 monotherapy in recurrent EEC (Group 1)

        2. DKN-01+paclitaxel in recurrent EEC (Group 2)

        3. DKN-01 monotherapy in recurrent EOC (Group 3)

        4. DKN-01+paclitaxel in recurrent EOC (Group 4)
    

Trial Arms

NameTypeDescriptionInterventions
Group 1ExperimentalDKN-01 monotherapy in recurrent EEC
  • DKN-01
Group 2ExperimentalDKN-01+paclitaxel in recurrent EEC
  • Paclitaxel
  • DKN-01
Group 3ExperimentalDKN-01 monotherapy in recurrent EOC
  • DKN-01
Group 4ExperimentalDKN-01+paclitaxel in recurrent EOC
  • Paclitaxel
  • DKN-01

Eligibility Criteria

        Inclusion Criteria:

          1. Diagnosis:

               1. Epithelial Endometrial Cancer: histologically confirmed diagnosis (by either
                  primary surgical specimen or biopsy for recurrence) of recurrent previously
                  treated EEC.

               2. Epithelial Ovarian Cancer: histologically confirmed diagnosis (by either primary
                  surgical specimen or biopsy for recurrence) of recurrent
                  platinum-resistant/refractory EOC (i.e., disease recurrence within 6 months of
                  completion of or progression during platinum-based chemotherapy).

             Note that patients with germ cell, sex cord stroma, carcinosarcoma, or sarcoma are
             eligible only if the tumor has a mixed endometrioid component with a documented Wnt
             signaling alteration.

          2. Refractory or intolerant to at least one prior standard therapy(ies) for metastatic or
             locally advanced disease.

               1. If prior therapy consisted of palliative chemoradiation therapy, it will be
                  considered one line of therapy.

               2. Prior treatment with paclitaxel as part of definitive therapy regimen is
                  acceptable, provided the patient is not intolerant of paclitaxel.

               3. Patients who are not eligible to receive paclitaxel will be allowed to receive
                  single agent DKN-01.

          3. Tumor tissue for mandatory pre-treatment and on-treatment biopsies.

          4. One or more tumors measurable on radiographic imaging as defined by RECIST 1.1.

          5. Ambulatory and ≥18 years of age.

          6. ECOG performance status (PS) of 0 or 1

             a. ECOG PS of 2 may be eligible upon the review and approval of the Medical Monitor.

          7. Estimated life expectancy of at least 3 months, in the judgment of the Investigator.

          8. Disease-free of active second/secondary or prior malignancies for ≥2 years with the
             exception of currently treated basal cell, squamous cell carcinoma of the skin, or
             carcinoma in-situ of the cervix or breast.

          9. Acceptable liver, renal, hematologic and coagulation function

         10. Females of child bearing potential and male partners of female patients must agree to
             use adequate contraception during the study and for 6 months after their last dose of
             study drug.

         11. Reliable and willing to make themselves available for the duration of the study and
             are willing to follow study-specific procedures.

         12. Provided written informed consent prior to any study-specific procedures.

        Exclusion Criteria:

          1. Patients with the following pure histologies of endometrial or ovarian cancer are not
             eligible for enrollment: germ cell, sex cord stroma, carcinosarcoma, or sarcoma.

          2. New York Heart Association Class III or IV cardiac disease, myocardial infarction
             within the past 6 months, or unstable arrhythmia.

          3. Fridericia-corrected QT interval (QTcF) > 470 msec (female) or history of congenital
             long QT syndrome.

          4. Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study
             entry requiring systemic therapy.

          5. Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface
             antigen (HBSAg), or hepatitis C antibodies (HCAb), unless hepatitis C virus
             ribonucleic acid (HCV RNA) undetected/negative.

          6. History of major organ transplant (i.e., heart, lungs, liver, or kidney).

          7. History of autologous/allogenic bone marrow transplant.

          8. Serious nonmalignant disease

          9. Pregnant or nursing.

         10. History of osteonecrosis of the hip or have evidence of structural bone abnormalities
             in the proximal femur on MRI scan that are symptomatic and clinically significant.

         11. Symptomatic central nervous system (CNS) malignancy or metastasis.

         12. Known osteoblastic bony metastasis

         13. Treatment with surgery or chemotherapy within 21 days prior to study entry (42 days
             for nitrosoureas or mitomycin C)

         14. Any hormonal therapy directed at the malignant tumor must be discontinued at least one
             week prior to study entry.

         15. Clinically significant peripheral neuropathy at the time of study entry. Patients with
             pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01

         16. History of hypersensitivity reactions to paclitaxel or other drugs formulated in
             Cremophor® EL (polyoxyethylated castor oil). Patients who exhibit these
             hypersensitivities will be eligible to receive single agent DKN-01

         17. Prior radiation therapy within 14 days prior to study entry

         18. Currently receiving any other investigational agent or received an investigational
             agent within last 30 days of study entry.

         19. Previously treated with an anti-DKK1 therapy

         20. Significant allergy to a pharmaceutical therapy that, in the opinion of the
             Investigator, poses an increased risk to the patient

         21. Active substance abuse
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:Female
Healthy Volunteers:No

Primary Outcome Measures

Measure:To determine the objective response rate (ORR).
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:

Secondary Outcome Measures

Measure:To determine the objective disease control rate (ODCR).
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:
Measure:To determine overall survival (OS).
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:
Measure:To determine progression-free survival (PFS).
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:
Measure:To evaluate the adverse drug reactions and toxicities as evaluated by NCI CTCAE, version 4.03 as DKN-01 as monotherapy or in combination with paclitaxel
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:
Measure:To evaluate additional measures of efficacy, including time to progression (TTP)
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:
Measure:To evaluate additional measures of efficacy, including duration of response (DoR)
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:
Measure:To evaluate additional measures of efficacy, including duration of complete response (DoCR)
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:
Measure:To evaluate additional measures of efficacy, including time to treatment failure (TTTF).
Time Frame:Baseline to study completion (approximately 6 months)
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Leap Therapeutics, Inc.

Trial Keywords

  • epithelial histology
  • Wnt pathway
  • DKK1

Last Updated